• Explore /
  • Poster
  • / The MILO (MEK inhibitor in low-grade serous ovarian cancer)/ENGOT-ov11 study: A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician’s choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum.

The MILO (MEK inhibitor in low-grade serous ovarian cancer)/ENGOT-ov11 study: A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician’s choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum.

Abstract Poster

Authors

Bradley Monk

Bradley J. Monk

University of Arizona Cancer Center and Creighton University School of Medicine at Dignity Health St. Joseph's Hospital and Medical Center, Phoenix, AZ

Bradley J. Monk , Rachel N. Grisham , Christian Marth , Susana N. Banerjee , Felix Hilpert , Robert L. Coleman , Eric Pujade-Lauraine , Sandro Pignata , Mansoor Raza Mirza , Amit M. Oza , Josep M. del Campo , Martin Klaus Oehler , Adam James , Janna Christy-Bittel , Emma Barrett , Adam P. Boyd , Ignace Vergote

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT01849874

Citation

J Clin Oncol 33, 2015 (suppl; abstr TPS5610)

DOI

10.1200/jco.2015.33.15_suppl.tps5610

Abstract #

TPS5610

Poster Bd #

165b

Abstract Disclosures

Similar Posters

First Author: Bradley J. Monk

First Author: Sanne Huijberts

First Author: Susana N. Banerjee

First Author: Rachel N. Grisham